BRPI0516134A - neurotoxinas de clostridium para uso na cicatrização de tecidos - Google Patents

neurotoxinas de clostridium para uso na cicatrização de tecidos

Info

Publication number
BRPI0516134A
BRPI0516134A BRPI0516134-7A BRPI0516134A BRPI0516134A BR PI0516134 A BRPI0516134 A BR PI0516134A BR PI0516134 A BRPI0516134 A BR PI0516134A BR PI0516134 A BRPI0516134 A BR PI0516134A
Authority
BR
Brazil
Prior art keywords
neurotoxins
clostridium
tissue
damaged
healing
Prior art date
Application number
BRPI0516134-7A
Other languages
English (en)
Inventor
Harold Victor Taylor
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI0516134A publication Critical patent/BRPI0516134A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

NEUROTOXINAS DE CLOSTRIDIUM PARA USO NA CICATRIZAçãO DE TECIDOS. Neurotoxinas de Clostridium de ocorrência natural e/ou modificadas, que incluem aquelas neurotoxinas livres de proteínas de formação de complexo que formam complexos com neurotoxinas de Clostridium, são usadas para melhorar a cicatrização de superfície danificada ou tecido superficial de um paciente por administração local ou na proximidade do tecido danificado. Tais neurotoxinas podem ser vantajosamente empregadas na cicatrização de ferimentos e para evitar a formação de cicatrizes, e têm aplicabilidade na área de oftalmologia, por exemplo, no tratamento de tecido corneano danificado, por exemplo, por fechamento de olhos inflamados. Uma modalidade adicional inclui o uso diagnóstico para a avaliação de administração eficaz de toxina e medicamentos para uso nela.
BRPI0516134-7A 2004-09-27 2005-09-27 neurotoxinas de clostridium para uso na cicatrização de tecidos BRPI0516134A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61339204P 2004-09-27 2004-09-27
PCT/GB2005/003728 WO2006035225A1 (en) 2004-09-27 2005-09-27 Clostridial neurotoxins for use in tissue healing

Publications (1)

Publication Number Publication Date
BRPI0516134A true BRPI0516134A (pt) 2008-08-26

Family

ID=35355850

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516134-7A BRPI0516134A (pt) 2004-09-27 2005-09-27 neurotoxinas de clostridium para uso na cicatrização de tecidos

Country Status (13)

Country Link
US (1) US20060067950A1 (pt)
EP (1) EP1799254A1 (pt)
KR (1) KR20070057862A (pt)
CN (1) CN101027083A (pt)
AU (1) AU2005288758A1 (pt)
BR (1) BRPI0516134A (pt)
CA (1) CA2580122A1 (pt)
EA (1) EA200700739A1 (pt)
IL (1) IL182153A0 (pt)
MX (1) MX2007003407A (pt)
NO (1) NO20072155L (pt)
WO (1) WO2006035225A1 (pt)
ZA (1) ZA200702484B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US10076558B2 (en) 2014-02-18 2018-09-18 Rnw Skn, Llc Prophylactic normalization of cutaneous wound repair
CA3057302A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for use in therapy
AU2018237205A1 (en) * 2017-03-22 2019-10-31 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
CN107469065B (zh) * 2017-07-19 2021-05-18 广州医科大学 类蛇毒三胜肽在制备用于治疗皮肤溃疡的药物中的应用
US20190183987A1 (en) * 2017-12-18 2019-06-20 Bonti, Inc. Neurotoxins for use in minimizing scarring

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216589T1 (de) * 1996-11-27 2002-05-15 William J Binder Neurotoxine zur behandlung von hauterkrankungen bei säugetieren
MXPA01004254A (es) * 1998-10-27 2002-04-24 Mayo Foundation Metodos para intensificar la curacion de heridas.
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders

Also Published As

Publication number Publication date
WO2006035225A1 (en) 2006-04-06
ZA200702484B (en) 2008-11-26
CN101027083A (zh) 2007-08-29
EP1799254A1 (en) 2007-06-27
AU2005288758A1 (en) 2006-04-06
NO20072155L (no) 2007-04-26
KR20070057862A (ko) 2007-06-07
MX2007003407A (es) 2007-05-23
EA200700739A1 (ru) 2007-10-26
US20060067950A1 (en) 2006-03-30
IL182153A0 (en) 2007-07-24
CA2580122A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
BRPI0516134A (pt) neurotoxinas de clostridium para uso na cicatrização de tecidos
ECSP077328A (es) Neurotoxinas clostridiales para uso en la cicatrización de tejidos
Moffatt et al. Venous leg ulcers: patient concordance with compression therapy and its impact on healing and prevention of recurrence
Gómez-Cardero et al. Postoperative analgesia in TKA: ropivacaine continuous intraarticular infusion
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
Zhou et al. Modified dextrose prolotherapy for recurrent temporomandibular joint dislocation
CR9351A (es) Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica
BRPI0513168A (pt) memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia
ES2249490T3 (es) Articulos quirurgicos.
CY1107615T1 (el) Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
BR0316906A (pt) administração do capsaicinoides
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
BR0315319A (pt) Terapias e procedimentos dentais com toxina botulìnica
Balcin et al. A comparative study of two methods of surgical treatment for painful neuroma
Wang et al. Intra-articular injection of hyaluronic acid for the reduction in joint adhesion formation in a rabbit model of knee injury
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
GB0507598D0 (en) Composition
Taylor et al. Efficacy of variable‐particle hyaluronic acid dermal fillers in patients with skin of color: a randomized, evaluator‐blinded comparative trial
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
BRPI0418138A (pt) medicamento compreendendo ptx3, sozinho ou em combinação com tsg-6, para tratar doenças degenerativas de cartilagem e ósseas e tratar infertilidade feminina
Matthews-Brzozowska et al. Mesotherapy–a method of facial skin rejuvenation from an interdisciplinary perspective on improving facial aesthetics
BRPI0404050A (pt) Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.